Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Breast Cancer

Free Subscription 24.02.2020 4 Ann Oncol 1 Ann Surg Oncol 2 Anticancer Res 1 BMC Cancer 2 Br J Cancer 2 Breast Cancer 3 Breast Cancer Res 8 Breast Cancer Res Treat 4 Breast J 1 Cancer Res 1 Clin Breast Cancer 2 Clin Cancer Res 2 Eur Radiol 4 Int J Cancer 2 J Surg Oncol 1 Lancet 1 Nat Rev Clin Oncol 4 Oncogene 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Oncol

1. MOSELE F, Stefanovska B, Lusque A, Tran Dien A, et al
   Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
   Ann Oncol. 2020;31:377-386.
   PubMed     Text format     Abstract available
   
   
2. BARROSO-SOUSA R, Jain E, Cohen O, Kim D, et al
   Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
   Ann Oncol. 2020;31:387-394.
   PubMed     Text format     Abstract available
   
   
3. MOSS J, Zick A, Grinshpun A, Carmon E, et al
   Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer.
   Ann Oncol. 2020;31:395-403.
   PubMed     Text format     Abstract available
   
   
4. MAVROUDIS D, Saloustros E, Malamos N, Kakolyris S, et al
   Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volu
   Ann Oncol. 2020;31:444-445.
   PubMed     Text format    
   
   

   
   Ann Surg Oncol

5. REYES SA, De La Cruz LM, Ru M, Pisapati KV, et al
   Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
   Ann Surg Oncol. 2019;26:3397-3408.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

6. MIMOUN C, Zeller A, Seror J, Majoulet L, et al
   A Pre-operative Score to Discriminate Fibroepithelial Lesions of the Breast: Phyllode Tumor or Fibroadenoma?
   Anticancer Res. 2020;40:1095-1100.
   PubMed     Text format     Abstract available
   
   
7. PISTOLESE CA, Lamacchia F, Tosti D, Anemona L, et al
   Reducing the Number of Unnecessary Percutaneous Biopsies: The Role of Second Opinion by Expert Breast Center Radiologists.
   Anticancer Res. 2020;40:939-950.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. EE C, Cave AE, Naidoo D, Bilinski K, et al
   Weight before and after a diagnosis of breast cancer or ductal carcinoma in situ: a national Australian survey.
   BMC Cancer. 2020;20:113.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

9. BENS A, Dehlendorff C, Friis S, Cronin-Fenton D, et al
   The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study.
   Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0747.
   PubMed     Text format     Abstract available
   
   
10. WONG EM, Southey MC, Terry MB
    Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-019-0720.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer

11. SAFABAKHSH M, Imani H, Shab-Bidar S
    Higher dietary total antioxidant capacity is not associated with risk of breast cancer in Iranian women.
    Breast Cancer. 2020 Feb 17. pii: 10.1007/s12282-020-01059.
    PubMed     Text format     Abstract available
    
    
12. YAMASHIRO H, Iwata H, Masuda N, Yamamoto N, et al
    Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Breast Cancer. 2020 Feb 14. pii: 10.1007/s12282-020-01057.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

13. YANES T, Young MA, Meiser B, James PA, et al
    Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field.
    Breast Cancer Res. 2020;22:21.
    PubMed     Text format     Abstract available
    
    
14. VAKLAVAS C, Roberts BS, Varley KE, Lin NU, et al
    TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Breast Cancer Res. 2020;22:22.
    PubMed     Text format     Abstract available
    
    
15. LE CORNET C, Walter B, Sookthai D, Johnson TS, et al
    Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-beta, and ERbeta: results from the EPIC-Heidelberg cohort.
    Breast Cancer Res. 2020;22:23.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

16. YUNG R, Ray RM, Roth J, Johnson L, et al
    The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Feb 15. pii: 10.1007/s10549-020-05572.
    PubMed     Text format     Abstract available
    
    
17. PAN K, Ray RM, Cauley JA, Shadyab AH, et al
    Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05576.
    PubMed     Text format     Abstract available
    
    
18. ALTUNDAG K
    Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
    Breast Cancer Res Treat. 2020;179:763.
    PubMed     Text format    
    
    
19. ZHANG L, Hsieh MC, Petkov V, Yu Q, et al
    Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05557.
    PubMed     Text format     Abstract available
    
    
20. CORONA SP, Bortul M, Scomersi S, Bigal C, et al
    Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05565.
    PubMed     Text format     Abstract available
    
    
21. KIM M, Kim H, Ahn SH, Tabatabaie V, et al
    Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05566.
    PubMed     Text format     Abstract available
    
    
22. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Feb 17. pii: 10.1007/s10549-020-05564.
    PubMed     Text format     Abstract available
    
    
23. CHEN L, Fu F, Huang M, Lv J, et al
    The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Breast Cancer Res Treat. 2020 Feb 18. pii: 10.1007/s10549-020-05573.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

24. PREAT F, Rondelli M, Delrue P, Anne-Sophie H, et al
    Contralateral axillary sentinel node: The hidden pathway in breast cancer.
    Breast J. 2020 Feb 18. doi: 10.1111/tbj.13777.
    PubMed     Text format    
    
    
25. WEI CH, West R, Schmolze D, Apple SK, et al
    Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial.
    Breast J. 2020 Feb 20. doi: 10.1111/tbj.13771.
    PubMed     Text format    
    
    
26. WAKELEY ME, Bare CF, Pine R, Dube C, et al
    A social media survey of women who do not pursue reconstruction after mastectomy for breast cancer: Characterizing the "Going Flat" movement.
    Breast J. 2020 Feb 18. doi: 10.1111/tbj.13781.
    PubMed     Text format    
    
    
27. SILVA TB, Cardoso MAS, Ramim JE, Bergmann A, et al
    Pain-relievers prescription after bone metastasis detection in breast cancer patients: A Brazilian reference cancer hospital experience.
    Breast J. 2020 Feb 18. doi: 10.1111/tbj.13782.
    PubMed     Text format    
    
    

    
    Cancer Res

28. BORGES VF, Lyons TR, Germain D, Schedin P, et al
    Postpartum involution and cancer: an opportunity for targeted breast cancer prevention and treatments?
    Cancer Res. 2020 Feb 19. pii: 0008-5472.CAN-19-3448.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

29. NACK E, Koffer PP, Blumberg CS, Leonard KL, et al
    New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab.
    Clin Breast Cancer. 2019 Dec 19. pii: S1526-8209(19)30765.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

30. SANTA-MARIA CA, Coughlin JW, Sharma D, Armanios M, et al
    The Effects of a Remote-Based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2935.
    PubMed     Text format     Abstract available
    
    
31. CLIFTON GTT, Hale D, Vreeland TJ, Hickerson AT, et al
    Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients.
    Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2741.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

32. ZHU Y, Zhang Y, Ma Y, Li H, et al
    Correction to: Cone-beam breast CT features associated with HER2/neu overexpression in patients with primary breast cancer.
    Eur Radiol. 2020 Feb 17. pii: 10.1007/s00330-020-06673.
    PubMed     Text format     Abstract available
    
    
33. HARADA TL, Uematsu T, Nakashima K, Sugino T, et al
    Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
    Eur Radiol. 2020 Feb 15. pii: 10.1007/s00330-020-06662.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

34. PERSSON H, Sokilde R, Hakkinen J, Vallon-Christersson J, et al
    Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer.
    Int J Cancer. 2020 Feb 17. doi: 10.1002/ijc.32927.
    PubMed     Text format     Abstract available
    
    
35. LIU ZH, Chen ML, Zhang Q, Zhang Y, et al
    ZIC2 is downregulated and represses tumor growth via the regulation of STAT3 in breast cancer.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32922.
    PubMed     Text format     Abstract available
    
    
36. JOHN EM, Phipps AI, Hines LM, Koo J, et al
    Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and race/ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32923.
    PubMed     Text format     Abstract available
    
    
37. FIGUEROA JD, Davis Lynn BC, Edusei L, Titiloye N, et al
    Reproductive Factors and Risk of Breast Cancer by Tumor Subtypes among Ghanaian Women: A Population-based Case-control Study.
    Int J Cancer. 2020 Feb 18. doi: 10.1002/ijc.32929.
    PubMed     Text format     Abstract available
    
    

    
    J Surg Oncol

38. ALTUNDAG K
    Late relapse rates in patients with early-stage hormone receptor-positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy.
    J Surg Oncol. 2020 Feb 17. doi: 10.1002/jso.25857.
    PubMed     Text format    
    
    
39. BURKBAUER L, Goldbach M, Pomponio M, Tchou J, et al
    Response to "Late relapse rates in patients with early-stage hormone receptor positive and HER2+ breast cancer treated with adjuvant chemotherapy and neoadjuvant chemotherapy".
    J Surg Oncol. 2020 Feb 17. doi: 10.1002/jso.25867.
    PubMed     Text format    
    
    

    
    Lancet

40. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.
    PubMed     Text format    
    
    

    
    Nat Rev Clin Oncol

41. KILLOCK D
    CDK4/6 inhibitors prolong OS.
    Nat Rev Clin Oncol. 2019;16:722.
    PubMed     Text format    
    
    

    
    Oncogene

42. BROWN TP, Bhattacharjee P, Ramachandran S, Sivaprakasam S, et al
    The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment.
    Oncogene. 2020 Feb 19. pii: 10.1038/s41388-020-1216.
    PubMed     Text format     Abstract available
    
    
43. FARHAT D, Ghayad SE, Icard P, Le Romancer M, et al
    Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines.
    Oncogene. 2020 Feb 14. pii: 10.1038/s41388-020-1211.
    PubMed     Text format     Abstract available
    
    
44. GONG C, Tsoi H, Mok KC, Cheung J, et al
    Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer.
    Oncogene. 2020 Feb 17. pii: 10.1038/s41388-020-1210.
    PubMed     Text format     Abstract available
    
    
45. BESSOU M, Lopez J, Gadet R, Deygas M, et al
    The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production.
    Oncogene. 2020 Feb 17. pii: 10.1038/s41388-020-1212.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

46. CHENG HG, Gonzalez-Reymundez A, Li I, Pathak A, et al
    Breast cancer survival and the expression of genes related to alcohol drinking.
    PLoS One. 2020;15:e0228957.
    PubMed     Text format     Abstract available
    
    
47. JAMSHIDI N, Chang J, Mock K, Nguyen B, et al
    Correction: Evaluation of the predictive ability of ultrasound-based assessment of breast cancer using BI-RADS natural language reporting against commercial transcriptome-based tests.
    PLoS One. 2020;15:e0229584.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: